T-28: The Importance of Human Translation for Successful Preclinical Drug Discovery and Cardiac Safety
Poster Presenter
Andre Ghetti
Chief Executive Officer
AnaBios United States
Objectives
The translation from preclinical animal models to human outcomes continues to be unreliable at best. Novel approaches are needed to establish more reliable translational paradigms. AnaBios has pioneered a preclinical strategy that enables the interrogation of human primary cells from organ donors.
Method
By combining novel technologies and reagents that minimize donor organ ischemia-reperfusion damage with innovative cell- and tissue- interrogation methods, it is now possible to measure drug effects in human ex-vivo preparations at the preclinical stage.
Results
We have applied these methodologies to discovery programs in several therapeutic areas and case studies in pain and cardiac disease will be discussed. Furthermore, the use of human primary cells in preclinical safety assessment, has the potential to fill critical translational gaps.
Conclusion
This approach provides data that are highly predictive of clinical outcomes. In addition, the ability to test drug activity in human cells recovered from patient donors in the relevant pathological state provides a highly valuable paradigm to assess the true therapeutic potential of new drugs.
